Au8, an experimental ALS therapy. CNM-Au8 has been associated with NfL reductions, a biomarker finding linked to longer ...
High-dose dazucorilant showed significant survival benefit in a Phase 2 ALS trial. It reduced mortality risk by up to 87% over two years for ALS patients. A pivotal Phase 3 trial for this ALS therapy ...
PIONEER-ALS, a clinical trial evaluating VTx-002 as a treatment for ALS, has been given a green light to launch study sites in three European nations. The therapy targets toxic TDP-43 protein clumps, ...
May is ALS Awareness Month, and in the U.S. and around the world, organizations are educating, sponsoring events, and encouraging the community to join them in taking action, providing financial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results